Navigation Links
WuXi PharmaTech Announces Licensing Agreement for Patient-Derived Xenograft Models with Mayo Clinic's Center for Individualized Medicine
Date:11/4/2013

SHANGHAI, Nov. 4, 2013 /PRNewswire/ -- WuXi PharmaTech (NYSE: WX), a leading pharmaceutical, biotechnology and medical device research and development outsourcing company with operations in China and the United States, today announced a licensing agreement with Mayo Clinic's Center for Individualized Medicine to expand WuXi's collection of patient-derived xenograft (PDX) mouse models.  These models will support the cancer drug discovery and personalized medicine efforts of WuXi's global customers.

Under this agreement, WuXi has been granted an exclusive license for a panel of patient-derived xenograft models for prevailing cancers in Western countries that have been developed in connection with the center's research and patient care.  The Mayo collection supplements WuXi's unique and extensive Chinese PDX collection, which includes more than 500 Chinese patient-derived xenograft models, more than 220 of which have been deep-sequenced using whole exome sequencing at 100X.  By combining PDX models derived from cancer tissues of patients representing Chinese and Western ancestries, WuXi is creating a single platform to allow its global customers to select highly relevant models with a higher probability of success for testing targeted therapies.

"This agreement with the internationally renowned Mayo Clinic enables WuXi to provide the global research community with a unique single resource that will help advance cancer research through a more relevant and clinically directed approach," said Dr. Ge Li, Chairman and CEO of WuXi.  "We look forward to working with world-class organizations like Mayo Clinic to further strengthen our integrated, open-access R&D services platform, which enables anyone and any company to discover and develop new medicines for improved patient care."

"We are delighted to work with WuXi, an organization with a strong reputation and industry leadership, to make our PDX models broadly available to the global cancer research community," said Dr. Gianrico Farrugia, Director of Mayo Clinic's Center for Individualized Medicine. "We hope use of these models leads to more predictive approaches to the discovery and development of personalized cancer therapies for patients."

Mayo Clinic has a financial interest in the technology mentioned in this news release.  Revenue Mayo receives is used to support the clinic's not-for-profit mission in patient care, education and research.

About WuXi PharmaTech

As a research-driven and customer-focused company, WuXi PharmaTech (Cayman) Inc. provides a broad and integrated portfolio of laboratory and manufacturing services throughout the drug and medical device R&D process.  WuXi PharmaTech's services are designed to assist its global partners in shortening the cycle and lowering the cost of drug and medical device R&D.  WuXi AppTec is the name for the operating subsidiaries of WuXi PharmaTech.  For more information, please visit: http://www.wuxiapptec.com.

For more information, please contact:

Ronald Aldridge
Director of Investor Relations
WuXi PharmaTech
1-201-585-2048
ron_aldridge@wuxiapptec.com

Aaron Shi
Associate Director of Corporate Communications
WuXi PharmaTech
+86-21-5046-4362
aaron_shi@wuxiapptec.com


'/>"/>
SOURCE WuXi PharmaTech
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Zacks.com featured expert Kevin Matras highlights: Core Laboratories NV, Invesco Ltd., Medtronic, Inc., Willbros Group Inc. and WuXi PharmaTech Inc.
2. WuXi PharmaTech Schedules First-Quarter 2013 Earnings Release
3. Breckenridge announces agreement with Aptalis Pharmatech to market Propranolol Hydrochloride Extended-Release Capsules
4. WuXi PharmaTech Receives Letter from AAALAC Commending Animal Care at Suzhou Toxicology Facility as "Exemplary"
5. WuXi PharmaTech Announces Fourth-Quarter and Full-Year 2012 Results, Share Repurchase Program
6. WuXi PharmaTech and Open Monoclonal Technology Expand Human Antibody Development and Commercial Opportunities for Asian Regional and Global Pharmaceutical Companies
7. WuXi PharmaTech Schedules Fourth-Quarter 2012 Earnings Release
8. WuXi PharmaTech Presents the 2012 Life Science and Chemistry Awards
9. WuXi PharmaTech Announces Shareholder Resolutions Adopted at 2012 Annual General Meeting
10. WuXi PharmaTech Celebrates Dr. Joseph Vaccas Induction into American Chemical Societys Medicinal Chemistry Hall of Fame
11. WuXi PharmaTech and Open Monoclonal Technology Announce OmniRat(TM) Antibody Collaboration
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/8/2016)... ANGELES , Dec. 8, 2016  Hanson ... manufacturing of dissolution testing and diffusion testing instruments ... been acquired by Teledyne Instruments, Inc. ("Teledyne"). The ... long-proven line of precision testing instruments, as well ... accelerating development of new products and services. ...
(Date:12/8/2016)... 2016  Haemonetics Corporation (NYSE: HAE ) has ... an innovative software suite designed to help customers drive efficiency ... of NextGen DMS 4 improves core features and introduces innovations ... liter of plasma collected, enhancing quality and regulatory compliance and ... ...
(Date:12/8/2016)... Inc . has announced regulatory approval by CFDA and product launch in ... (GERD). Continue Reading ... ... by Professor Jun Liu, Director of Endoscopy at Wuhan Union Hospital ... "We are very pleased that Mederi products are now available in ...
Breaking Medicine Technology:
(Date:12/8/2016)... PLAINS, N.Y., and JENNERSVILLE, Pa. (PRWEB) , ... ... ... to announce that Penn Medicine Southern Chester County, a Property owned by an ... The $23 million, 72,000 square foot Penn Medicine Southern Chester County ambulatory care ...
(Date:12/8/2016)... Boston (PRWEB) , ... December 08, 2016 , ... ... shareholders with global law firm Greenberg Traurig, LLP, will speak at DeviceTalks West, Dec. ... sponsor of the DeviceTalks series, and attorneys from the firm’s global Life Sciences & ...
(Date:12/8/2016)... N.J. (PRWEB) , ... December 08, 2016 , ... ... delivery technologies and development solutions for drugs, biologics and consumer health products, today ... PSCI was set up in 2006 as a non-profit organization to unite pharmaceutical ...
(Date:12/8/2016)... Peachtree City, Ga (PRWEB) , ... December 08, ... ... and moving as soon after surgery as possible. With this in mind, SIGVARIS ... vein thrombosis (DVT or blood clot) during bed rest and provide the benefits ...
(Date:12/8/2016)... ... December 08, 2016 , ... ... services from offices headquartered in Hamilton County, is embarking on a charity drive ... specializes in finding new homes for orphaned or neglected senior dogs in the ...
Breaking Medicine News(10 mins):